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Background: Carboplatin/paclitaxel (CP), with or without sorafenib, result in objective response rates of 18–20 % in
unselected chemotherapy-naïve patients. Molecular predictors of survival and response to CP-based chemotherapy in
metastatic melanoma (MM) are critical to improving the therapeutic index.
Intergroup trial E2603 randomized MM patients to CP with or without sorafenib. Expression data were collected from
pre-treatment formalin-fixed paraffin-embedded (FFPE) tumor tissues from 115 of 823 patients enrolled on E2603. The
selected patients were balanced across treatment arms, BRAF status, and clinical outcome. We generated data using
Nanostring array (microRNA (miRNA) expression) and DNA-mediated annealing, selection, extension and ligation
(DASL)/Illumina microarrays (HT12 v4) (mRNA expression) with protocols optimized for FFPE samples. Integrative
computational analysis was performed using a novel Tree-guided Recursive Cluster Selection (T-ReCS) [1] algorithm
to select the most informative features/genes, followed by TargetScan miRNA target prediction (Human v6.2) and
mirConnX [2] for network inference.
Results: T-ReCS identified PLXNB1 as negatively associated with progression-free survival (PFS) and miR-659-3p as
the primary miRNA associated positively with PFS. miR-659-3p was differentially expressed based on PFS but not
based on treatment arm, BRAF or NRAS status. Dichotomized by median PFS (less vs greater than 4 months),
miR-659-3p expression was significantly different. High miR-659-3p expression distinguished patients with responsive
disease (complete or partial response) from patients with stable disease. miR-659-3p predicted gene targets include
NFIX, which is a transcription factor known to interact with c-Jun and AP-1 in the context of developmental processes
and disease.
Conclusions: This novel integrative analysis implicates miR-659-3p as a candidate predictive biomarker for MM patients
treated with platinum-based chemotherapy and may serve to improve patient selection.
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The incidence of melanoma has increased progressively
over the last 30 years with an estimated 76,100 new
cases in 2014 and a projected 9700 deaths (http://seer.
cancer.gov/statfacts/html/melan.html). The prognosis of
metastatic disease is historically poor, with 5-year sur-
vival rates of less than 6 % and median survival of 6 to 9
months [3, 4]. Until 2010, alkylating agents were the
mainstay of treatment but associated with response rates
less than 10–15 % [5, 6]. Platinum-based chemotherapy
with carboplatin and paclitaxel (CP) is associated with
response rates of 18–20 % in chemotherapy-naïve pa-
tients and 11–12 % in the second-line setting [7, 8]. Sig-
nificant therapeutic advances have been made in recent
years with FDA approval of the monoclonal antibody to
CTLA-4, ipilimumab, which results in durable responses
and improved overall survival (OS) in patients with
metastatic melanoma (MM) compared with peptide vac-
cine or dacarbazine [9]. Antibody therapies against PD-1
and PD-L1 have also been associated with durable re-
sponses in MM, and the first agent targeting this pathway
was granted FDA approval in September 2014 [10–12]. Fi-
nally, the selective targeting of BRAF activating mutations,
which occur in about half of melanomas, with vemurafe-
nib, dabrafenib, and trametinib, is associated with marked
clinical activity and improved OS compared with chemo-
therapy [13, 14].
Despite the recent successes of immunotherapy and
targeted therapy, chemotherapy continues to be a signifi-
cant modality utilized worldwide in MM, especially after
progression on immunotherapy and/or antitumor tar-
geted agents. Recalcitrance of melanoma to chemother-
apy is a significant issue due to limited response rates
and lack of predictive biomarkers of chemotherapy
benefit. Identification of biomarkers of response and sur-
vival for patients treated with chemotherapy is critical to
allow more refined application of this modality and im-
proving treatment outcomes. MicroRNAs (miRNAs) are
endogenous non-coding RNAs approximately 22 nucleo-
tides in length that regulate gene expression at the post-
transcriptional level and play an important role in the
regulation of tumor suppressor genes, oncogenes, and
genes involved in the epigenetic machinery and cancer
cell metastasis [15]. miR-15a, miR-16, and the let-7 fam-
ily function predominately as tumor suppressors, while
the miR-17-92 cluster functions as oncogenes [16–20].
Differential expression of four miRNAs (miR-205, miR-
23b, miR-146a, and miR-155) distinguishes melanoma
cell lines from nevi and primary or metastatic melanoma
[19]. Differential miRNA expression also distinguishes
among common melanoma histologic subtypes (superfi-
cial spreading melanoma vs nodular melanoma) and be-
nign nevi compared with either primary or metastatic
melanoma [21–24]. Of greatest importance, miRNAshave been shown to have prognostic implications in mel-
anoma. Downregulation of miR-125b in patients with
stage T2 primary cutaneous melanoma is associated with
the presence of micrometastatic disease to the sentinel
lymph node [25]. Analysis of primary and metastatic
melanoma specimens shows that overexpression of an
18-miRNA signature is significantly correlated with lon-
ger survival (defined as a post-recurrence survival of
more than 18 months) [26], indicating the value of miR-
NAs as candidate prognostic biomarkers. To date, there
have been no studies examining miRNAs as candidate
predictive biomarkers of response to chemotherapy in
metastatic melanoma.
The Eastern Cooperative Oncology Group (ECOG)
Study, E2603, was a phase III randomized controlled
clinical trial evaluating the addition of the unselective
multi-tyrosine kinase inhibitor, sorafenib, to platinum-
based chemotherapy in patients with previously un-
treated MM. This phase III trial was the first to examine
targeted therapy in melanoma but failed to meet its pri-
mary endpoint of demonstrating an OS benefit in MM
patients treated with CP alone vs CP with sorafenib. The
response rates and progression-free survival (PFS) were
similar in either treatment arm. In the present study,
our primary objective was to identify molecular predic-
tors of survival and response to CP-based chemotherapy
in the MM patients treated on E2603. We applied a
novel method for cluster selection [1] to miRNA and
gene expression data in this well-defined patient popula-
tion in an effort to identify miRNAs as candidate bio-
markers of prognosis and response to platinum-based
chemotherapy. We then performed novel integrative
analysis to construct a proposed genome-wide regulatory
network, which lends insight into the role of our candi-
date miRNA biomarkers in the landscape of MM signal-
ing. To our knowledge, our study is the first to utilize
miRNAs as predictive biomarkers for therapy response
in melanoma.
Results and discussion
High-quality miRNA and mRNA expression data were
generated from legacy samples from 115 MM patients
treated on E2603. The clinicopathologic features for the
patients included in this analysis are summarized in
Table 1. The median PFS for this cohort of patients was
4.4 months and the median OS was 9.8 months.
PLXNB1 and RAD23 are associated with shortened PFS in
metastatic melanoma
Among the single genes selected with Tree-guided Re-
cursive Cluster Selection (T-ReCS), PLXNB1, a known
tumor suppressor of melanoma, had the most significant
negative association with PFS (p = 0.0001; Fig. 1a) [27,
28]. T-ReCS found gene RAD23 in the same group as
Table 1 Characteristics of patients treated on E2603 included in
this analysis
n = 115
Characteristic n (%)
Male sex 77 (67.0)
Median age, years (range) 59 (23–82)
AJCC stage
Unresectable stage III 16 (13.9)
M1a/M1b 41 (35.7)
M1c 58 (50.4)
Serum LDH at baseline
Normal 65 (56.5)
Above normal 47 (40.9)
ECOG performance status
0 67 (58.3)
1 48 (41.7)
Prior systemic therapy
None 52 (45.2)
Interferon, IL-2, GM-CSF 59 (51.3)
Investigational therapy 4 (3.5)
Treatment arm
Carboplatin/paclitaxel 58 (50.4)
Carboplatin/paclitaxel/sorafenib 57 (49.6)
BRAF status
Mutant 48 (41.8)
V600E 34 (29.6)
V600K 8 (7.0)
V600R 3 (2.6)
V600D 1 (0.9)
K601E 2 (1.7)
Wild-type 52 (45.2)
Unknown 15 (13.0)
NRAS status
Mutant 22 (19.1)
G13R 2 (1.7)
G13C 1 (0.9)
Q61R 9 (7.8)
Q61K 8 (7.0)
D61L 2 (1.7)
Wild-type 78 (67.8)
Unknown 15 (13.0)
Survival
Median OS, months (range) 9.8 (0.5–56.9)
Median PFS, months (range) 4.4 (0.5–42.1)
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sion repair mechanism, was also negatively associated
with PFS. In the other cluster, T-ReCS found BCMO1,
which encodes a key enzyme in beta-carotene metabol-
ism to vitamin A and is thus important for skin protec-
tion. BCMO1 was part of a very significant group
variable, which included LOC389936, a shRNA construct
with no known association with melanoma.
miR-659-3p is associated with improved PFS in metastatic
melanoma
T-ReCS identified miR-659-3p as the primary miRNA
associated positively with PFS (p = 0.008). The miR-659-
3p cluster also included miR-219-3p and miR-519-5p
(Fig. 1b), which had less significant or no association
with PFS (p = 0.036 and p = 0.12, respectively). We ex-
amined the Cox regression coefficients of this selected
cluster to interrogate our results. Indeed, all of these
miRNAs were positively associated with PFS. miR-659-
3p was not differentially expressed based on the treat-
ment arm (CP with sorafenib vs CP without sorafenib;
p = 0.6), BRAF mutation status (mutant vs wild-type;
p = 0.34) or NRAS mutation status (mutant vs wild-type;
p = 0.55). We dichotomized PFS less than 4 months vs
greater than 4 months, which is the median PFS of pa-
tients treated with CP with or without sorafenib on
E2603. Higher miR-659-3p expression remained prog-
nostic of longer PFS (p = 0.03). Further partitioning of
the dataset into terciles or quantiles did not yield any
significant results, presumably due to sample size. We
also noticed that higher miR-659-3p expression was gen-
erally observed in patients who achieved an objective re-
sponse (complete or partial response) as opposed to
patients with stable disease by Response Evaluation Cri-
teria In Solid Tumors (RECIST) (p = 0.04.)
miR-659-3p gene targets
miR-659-3p gene targets were inferred from TargetScan
Human v6.2 and from the mirConnX prior information
file [29]. The list of predicted targets included genes
relevant to the MAP kinase pathway (BRAF and NRAS),
genes relevant to the PI3K/MTOR, FGFR, and RAC1
pathways, as well as genes involved in DNA repair
(Table 2; Fig. 2b). However, the expression of most of
those genes was not significantly anti-correlated with
miR-659-3p expression. This might be explained by the
fact that each individual miRNA target usually decreases
the expression of the host gene by a small amount.
However, we did find a significant anti-correlation
(p < 0.01) between miR-659-3p and its predicted targets
COG6, ENOX2, HCFC2, NFIX, SDC1, and TSC22D2
(Fig. 2a). NFIX (nuclear factor 1 X-type), a member of
the NF-1 family, is particularly important since it has
been implicated in many developmental and biological
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Patients arranged from shortest to longest progression- free survival
Fig. 1 T-ReCS identified two major mRNA clusters (a) and one major cluster of three miRNAs (b) as predictive of progression-free survival (PFS),
represented at heatmaps. Patients are ordered from shortest to longest progression-free survival (c)
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is emerging as a potential therapeutic target [30–33].
Studies have also shown that it interacts with the onco-
genes c-Jun and AP-1 [34].
miR-331-3p distinguishes OS in metastatic melanoma
Running T-ReCS with OS as the outcome variable, we
found miR-331-3p as the primary miRNA positively as-
sociated with OS, while its cluster also included miR-93-
5p. miR-331-3p was not differentially expressed based on
the treatment arm (CP with sorafenib vs CP without so-
rafenib; p = 0.706), BRAF mutation status (mutant vs
wild-type; p = 0.1909) or NRAS mutation status (mutant
vs wild-type; p = 0.52).Conclusions
We have utilized a novel integrative analysis of miRNA
and gene expression data to identify molecular bio-
markers of PFS and response and found miR-659-3p ex-
pression to be positively associated with longer PFS,
distinguishing patients with disease that is responsive to
CP-based therapy. Characterization of the functional sig-
nificance of miR-659-3p has been limited to the neuro-
science literature, where it has been shown to bind a
common genetic variant of and regulate the expression
of the gene progranulin, which may significantly increase
the risk for frontotemporal dementia [35]. The func-
tional significance of miR-659-3p in cancer and melan-
oma is as of yet unknown. Of particular significance in
Table 2 Gene targets of interest of miR-659-3p identified using
TargetScan Human V6.2
Relevant pathway Gene target
MAPK BRAF
NRAS
MAP7
MAPK9
PI3K/MTOR PIK3C2A
FBXW2
RICTOR
FGFR FGF12
FGF18
RAC1 RAC1
DNA repair PARP16
TP53INP1
CDK19
ABCC1
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for miR-659-3p and the construction of a proposed regu-
latory network which may lend insight into the mechan-
istic role of miR-659-3p in response to cytotoxic
chemotherapy in melanoma.
Gene expression analysis showed PLXNB1 to be asso-
ciated with foreshortened PFS. PLXNB1 has previously
been shown to be lost in MM and in deeply invasive pri-
mary tumors and is strongly inhibited by MAP kinase
signaling in melanoma cells and melanocytes [27, 28]. In
preclinical models, plexin B1 suppressed proliferation,
enhanced migration, stimulated Akt activation and, of
particular interest, has been reported to render melan-
oma cell lines resistant to cisplatin-induced apoptosisA B
Fig. 2 Clustergram of genes whose expression was inversely correlated with
identified utilizing mirConnX software for network inference (b). Several onco
highlighted in gold. Genes are represented by squares, miRNAs by triangles, an
panel, genes in the KEGG melanoma pathway; top right corner, other cancer-r[28]. Plexin B1 has been shown to inhibit c-Met in re-
sponse to its ligand hepatocyte growth factor (HGF) and
is predicted to be a classic tumor suppressor protein in
melanomas in which progression is c-Met dependent
[28]. RAD23 was also identified in our model as associ-
ated with shorter PFS and is a component of the protein
complex that specifically complements the nucleotide
excision repair defect of xeroderma pigmentosum group
C (XP-c) cell extracts in vitro [36]. Furthermore, RAD23
has been shown to be downregulated in glutathione
S-transferase M1 (GSTM1)-null melanomas in patients
reporting histories of sunburns [37]. RAD23 has been
implicated as a biomarker of response to epigenetic ther-
apy, in particular HDAC inhibition, through a regulatory
circuit that involves RAD23B and HDAC6 [38, 39].
Predicted gene targets of miR-659-3p selected in our
analysis are genes important to the MAP kinase signal-
ing pathway, in particular BRAF and NRAS, and genes
relevant to the PI3K/MTOR, FGFR, and RAC1 path-
ways, as well as genes involved in DNA repair. BRAF, a
member of the RAF kinase family of serine/threonine
protein kinases, is mutated in 40–50 % of melanomas
and results most frequently from a valine (V) to glu-
tamic acid (E) substitution at residue 600 (BRAFV600E),
rendering mutant BRAF protein which no longer re-
quires dimerization for its activity, and is highly predict-
ive of therapeutic response to the specific BRAF
inhibitors, vemurafenib and dabrafenib. Mutations in
NRAS occur in 15–20 % of melanomas and result in
constitutive activation of the NRAS protein and en-
hanced MAP kinase signaling [40–42]. FGFR1 signaling
has been implicated in melanoma progression [43];
introduction of antisense oligonucleotides targeted to-
ward FGFR1 into metastatic cell lines results in de-
creased proliferation and signs of differentiation [44, 45];miR-659-3p expression in our dataset (a). Target predictions of miR-659-3p
genes known to be involved in melanoma disease mechanisms are
d transcription factors by circles. Left panel, anti-correlated genes; center
elated genes
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mary and metastatic melanomas grown in nude mice re-
sults in inhibition of tumor growth and induction of
apoptosis [46, 47]. RAC1, a member of the Rho family of
GTPases, is involved in cellular proliferation, survival,
motility, and invasiveness [48]. The RAC1 mutation
resulting in the substitution of proline for serine at resi-
due 29 is the most frequently mutated amino acid in
MM, after V600 mutations in BRAF and the glutamine
(Q) substitution at position 61 in NRAS. RAC1 muta-
tions are observed in 4 % of all melanomas and 9 % of
sun-exposed melanomas and may occur either inde-
pendently or in conjunction with BRAF and NRAS mu-
tations, suggesting growth advantages distinct from
activation of the MAP kinase signaling pathway [49, 50].
RAC1 and other members of the Rho family of GTPases
have been implicated as key modulators of sensitivity to
DNA-damaging agents; in particular, chemical inhibition
of RAC1 has been shown to sensitize drug-resistant
ovarian cancer cell lines to cisplatin [51–53].
While the association between miR-659-3p and these
predicted genes targets is intriguing, it is important to
note that our gene expression data do not show strong
correlations with miR-659-3p and at this point, these
findings are not confirmed. These findings do, however,
suggest biological relevance of miR-659-3p in the con-
text of known oncogenic drivers in melanoma, an associ-
ation which requires further investigation in future
studies. We did find a significant anti-correlation be-
tween miR-659-3p and a small set of genes. NFIX, which
has been implicated in many developmental and bio-
logical processes and diseases, is one of them and has
been shown to interact with known oncogenes. This
interaction may represent a clue as to functional rele-
vance of miR-659-3p and requires further validation.
Our study identified an association between miR-659-3p
and the clinical activity of CP-based therapy implicating
miR-659-3p as a candidate predictive biomarker in pa-
tients with metastatic melanoma. This analysis did not in-
clude untreated MM patients, and therefore, we are
unable to evaluate the prognostic value of miR-659-3p,
i.e., we are unable to assess if the association between
miR-659-3p and PFS persists in the absence of therapy.
These data were generated from formalin-fixed paraffin-
embedded (FFPE) legacy samples from a phase III multi-
center clinical trial that represents a limitation of this
study. Recovery of RNA from archival FFPE tissues can be
challenging due to strand breakage and cross-linking by
formalin fixation, which may inhibit polymerase in PCR-
based molecular assays. We overcame this challenge by
utilizing technology optimized for FFPE samples. Specific-
ally, the miRNA expression assay used in this study allows
for direct digital detection and counting of miRNAs in a
single reaction without the need for an amplification step.Another limitation is that this bio-analysis represents a
subset of the 823 patients enrolled on E2603. Archival tis-
sue was not compulsory in E2603, and therefore, genotyp-
ing information is available for only 179 patients treated
on this trial. It is notable that the patients included in this
analysis were similar to the overall E2603 population and
the population of patients for whom genotyping informa-
tion is available [7, 54].
This novel integrative analysis suggests miR-659-3p as a
candidate biomarker of response in MM patients treated
with platinum-based chemotherapy and may serve to im-
prove patient selection. To our knowledge, our study is
the first to identify a miRNA species as a predictor of ther-
apy outcome in metastatic melanoma. While our pro-
posed regulatory network embeds miR-659-3p in the
landscape of melanoma signaling, functional studies are
paramount to the validation of this miRNA as a mediator
of melanoma signaling. The value of the proposed regula-
tory network is to inform upon pathways which should be
interrogated as we continue to elucidate the role of miR-
659-3p as a predictive biomarker. Independent validation
of the predictive value of miR-659-3p is currently ongoing
in an independent cohort of MM patients treated with
carboplatin and paclitaxel.
Methods
Patients and study design
E2603 enrolled patients with pathologically confirmed
advanced unresectable or metastatic melanoma without
brain involvement, who had no previous treatment with
chemotherapeutic or MAPK pathway targeting agents.
The study design has been previously described [7]. Key
inclusion criteria were the presence of measurable dis-
ease by RECIST version 1.0, at least 18 years of age,
ECOG performance status of 0 or 1, and satisfactory
baseline organ function. Pre-treatment specimen collec-
tion was conducted as part of the clinical trial and ana-
lyzed with institutional review board approval. From the
823 patients enrolled on the E2603 clinical trial, 620
archival pre-treatment samples were available for ana-
lysis. One hundred and twenty pre-treatment formalin
fixed paraffin-embedded (FFPE) tumor tissues from 115
patients were selected to ensure a balanced representa-
tion of patients based on treatment arm, BRAF status,
and clinical outcome (PFS less than 4 months vs greater
than 4 months) were included in this analysis.
Treatment and assessment of response
The patients were randomized in a double-blind fashion
to receive CP, either with or without sorafenib. Paclitaxel
was administered at 225 mg/m2 over 3 h followed by
carboplatin AUC 6 IV over 30 min on day 1 of each
21-day cycle during cycles 1–4. During cycles 5 through
10, paclitaxel was administered at 175 mg/m2 IV over 3
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enib 400 mg or placebo was administered twice daily by
mouth on days 2 through 19 of each 21-day cycle. Upon
completion of 10 cycles of chemotherapy, sorafenib 400
mg twice daily by mouth or placebo was administered
daily until disease progression or intolerable toxicity.
Tumor response was assessed every 2 cycles during cy-
cles 1 through 10 and then every 3 cycles. Response was
defined by RECIST version 1.0.
Mutation profiling
Genotyping was performed using a custom iPlex Seque-
nom panel interrogating 74 mutations in 13 genes in the
Perelman School of Medicine Molecular Profiling Facil-
ity, as previously described [54].
RNA extraction
Total RNA was isolated from melanoma tissues using
the PerfectPure RNA Tissue kit (5Prime Inc., MD, USA)
at the University of Pittsburgh Cancer Institute (UPCI).
RNA was quantified using Ribogreen RNA quantitation
Kit (Molecular Probes, Eugene OR). RNA quality was
also evaluated by RNA integrity number using the Agi-
lent Bioanalyzer.
miRNA microarray expression profiling and gene
expression analysis
Profiling of miRNA levels was performed at the UPCI
utilizing technology optimized for FFPE samples: Nano-
string technology (Ncounter Human v2 miRNA Expres-
sion Assay) for miRNA analysis of 800 human miRNAs
was derived from miRBase v.18. Total RNA was used as
input for nCounter miRNA sample preparation reac-
tions. All sample preparation and processing were per-
formed according to the manufacturer’s protocol.
Following ligation, sample preparation reactions were
purified and diluted, and hybridization reactions were
performed by incubation at 65 °C for a minimum of 18
h. Hybridized probes were purified and counted on the
nCounter Prep Station and Digital Analyzer (Nano-
String) following the manufacturer’s instructions. For
each assay, a high-density scan (600 fields of view) was
performed. Whole-genome gene expression analysis was
also carried out using DNA-mediated annealing, selec-
tion, extension, and ligation (DASL)/Illumina HT-12 v4
Expression BeadChip, a technology optimized for FFPE
samples, at the UPCI according to the manufacturer’s
protocol.
Statistical analysis for mRNA and miRNA biomarkers
predictive of survival
We performed feature selection at the cluster level util-
izing a novel algorithm (T-ReCS) [1]. Briefly, starting
from a standard feature selection method against atarget variable (in our case, PFS or OS), T-ReCS expands
the single features into clusters of features according to
two statistical criteria that maintain the prediction ac-
curacy. The clusters are defined dynamically as groups
of similarly expressed genes. T-ReCS works in two steps.
First, it partitions the feature space into a tree structure
with the root being the set of all variables (mRNA or
miRNA genes, respectively), while each leaf is a single
variable. Each internal node in the tree represents a clus-
ter of variables, its descendants, whose values (expres-
sion) are similar. The lower in the tree a node is, the
more similar the patterns of its members are. For our
implementation, we use the tree produced by our Recur-
sive K-means Spectral Clustering (ReKS), which was pre-
viously developed for heterogeneous clinical data [29].
The second step of T-ReCS is feature selection operating
on the tree structure iteratively. Starting with a set of
variables (tree leafs) selected with any feature selection
method, it ascends the tree one level at a time and statis-
tically assesses whether the group variables (internal
nodes) retain the same predictive properties. For statis-
tical assessment, T-ReCS uses two conditional independ-
ence tests with p value thresholds determined by cross-
validation. For survival target variables, T-ReCS uses sur-
vival MMPC (sMMPC) [55] for single-variable selection.
The association between selected genes and survival was
tested using Cox regression (Cox proportional hazards
model) [56].Regulatory associations between predictive mRNA and
miRNA features
A regulatory network was constructed from the mRNA
and miRNA genes and their clusters that were selected
as characteristic of PFS. The mRNA targets of miRNAs
were predicted using TargetScan Human v6.2 [57], while
transcription factor (TF)→gene and TF→miRNA regula-
tory interactions were obtained from the prior (static)
network of mirConnX [2]. mirConnX is a user-friendly
web interface for inferring, displaying, and parsing mRNA
and miRNA gene regulatory networks. mirConnX infers
regulatory networks by combining expression correlation
values (dynamic network) with regulatory interactions ob-
tained from the literature and from computational predic-
tions (static network).
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